Type your tag names separated by a space and hit enter

ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

Evidence Summaries

Level of Evidence = A

ACE inhibitors reduce the risk of myocardial infarction, cardiovascular events and all-cause mortality in hypertensive patients with type 2 diabetes.

A systematic review 1 including 4 RCTs with a total of 2,180 subjects was abstracted in DARE. The analysis showed a statistically-significant benefit of ACE inhibitors on the outcome of acute myocardial infarction, compared with alternative treatments there was a 63% reduction (P <0.001) and the RR was 0.37 (95% CI: 0.24 to 0.57). On the outcome of cardiovascular events, compared with alternative treatments there was a 51% reduction and the RR was 0.49 (95% CI: 0.36 to 0.67). Also, there was a benefit of ACE inhibitors on the outcome of all-cause mortality, compared with alternative treatments there was a 62% reduction (P=0.010) and the RR was 0.57 (95% CI: 0.38 to 0.87). ACE inhibitors did not appear to be superior to other agents for the outcome of stroke in any of the trials, RR 0.76 (95% CI: 0.48 to 1.22).

The following decision support rules contain links to this evidence summary:

References

1. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000 Jul;23(7):888-92.  [PMID:10895836]


Copyright © 2017 Duodecim Medical Publications Limited.
ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.

Citation

"ACE Inhibitors and Other Antihypertensive Drugs in Patients With Type 2 Diabetes." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/456256/all/ACE_inhibitors_and_other_antihypertensive_drugs_in_patients_with_type_2_diabetes.
ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/456256/all/ACE_inhibitors_and_other_antihypertensive_drugs_in_patients_with_type_2_diabetes. Accessed March 24, 2019.
ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/456256/all/ACE_inhibitors_and_other_antihypertensive_drugs_in_patients_with_type_2_diabetes
ACE Inhibitors and Other Antihypertensive Drugs in Patients With Type 2 Diabetes [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 March 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/456256/all/ACE_inhibitors_and_other_antihypertensive_drugs_in_patients_with_type_2_diabetes.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes ID - 456256 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/456256/all/ACE_inhibitors_and_other_antihypertensive_drugs_in_patients_with_type_2_diabetes PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -